JP2016504039A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504039A5 JP2016504039A5 JP2015551759A JP2015551759A JP2016504039A5 JP 2016504039 A5 JP2016504039 A5 JP 2016504039A5 JP 2015551759 A JP2015551759 A JP 2015551759A JP 2015551759 A JP2015551759 A JP 2015551759A JP 2016504039 A5 JP2016504039 A5 JP 2016504039A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- glatiramer acetate
- group
- expression level
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749228P | 2013-01-04 | 2013-01-04 | |
| US61/749,228 | 2013-01-04 | ||
| US201361819481P | 2013-05-03 | 2013-05-03 | |
| US61/819,481 | 2013-05-03 | ||
| PCT/US2014/010103 WO2014107533A2 (en) | 2013-01-04 | 2014-01-02 | Characterizing a glatiramer acetate related drug product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504039A JP2016504039A (ja) | 2016-02-12 |
| JP2016504039A5 true JP2016504039A5 (enExample) | 2017-02-09 |
Family
ID=51061235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551759A Pending JP2016504039A (ja) | 2013-01-04 | 2014-01-02 | グラチラマーアセテート関連医薬品の特性決定 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140193827A1 (enExample) |
| EP (1) | EP2941274A4 (enExample) |
| JP (1) | JP2016504039A (enExample) |
| KR (1) | KR20150111945A (enExample) |
| CN (1) | CN105228651A (enExample) |
| AU (1) | AU2014204043A1 (enExample) |
| BR (1) | BR112015016169A2 (enExample) |
| CA (1) | CA2896957A1 (enExample) |
| CL (1) | CL2015001915A1 (enExample) |
| EA (1) | EA201591251A1 (enExample) |
| HK (1) | HK1216299A1 (enExample) |
| IL (2) | IL239692A0 (enExample) |
| MX (1) | MX2015008754A (enExample) |
| PE (1) | PE20151980A1 (enExample) |
| SG (1) | SG11201505210RA (enExample) |
| WO (1) | WO2014107533A2 (enExample) |
| ZA (1) | ZA201505367B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| CN105377308B (zh) | 2013-03-14 | 2019-07-26 | 迈兰公司 | 醋酸格拉替雷响应生物标志物mRNA效力测定 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| JP2018506275A (ja) | 2015-01-28 | 2018-03-08 | ジェネンテック， インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
| WO2017087866A1 (en) | 2015-11-20 | 2017-05-26 | Grand Valley State University | Nato3 mutant polypeptides and uses thereof |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| JP7276664B2 (ja) * | 2016-11-11 | 2023-05-18 | ロングエバーオン インコーポレイテッド | 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CN115044684A (zh) * | 2022-06-22 | 2022-09-13 | 四川大学华西医院 | lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7429374B2 (en) * | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| WO2004028339A2 (en) * | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| JP2009509142A (ja) * | 2005-09-19 | 2009-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法 |
| US8753833B2 (en) * | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| EP2365825A1 (en) * | 2008-11-18 | 2011-09-21 | Crossbeta Biosciences B.V. | Cross-beta structures as carriers in vaccines |
| NZ598661A (en) * | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
-
2014
- 2014-01-02 MX MX2015008754A patent/MX2015008754A/es unknown
- 2014-01-02 EA EA201591251A patent/EA201591251A1/ru unknown
- 2014-01-02 HK HK16104285.8A patent/HK1216299A1/zh unknown
- 2014-01-02 SG SG11201505210RA patent/SG11201505210RA/en unknown
- 2014-01-02 JP JP2015551759A patent/JP2016504039A/ja active Pending
- 2014-01-02 EP EP14735255.3A patent/EP2941274A4/en not_active Withdrawn
- 2014-01-02 CA CA2896957A patent/CA2896957A1/en not_active Abandoned
- 2014-01-02 WO PCT/US2014/010103 patent/WO2014107533A2/en not_active Ceased
- 2014-01-02 BR BR112015016169A patent/BR112015016169A2/pt not_active IP Right Cessation
- 2014-01-02 KR KR1020157021141A patent/KR20150111945A/ko not_active Withdrawn
- 2014-01-02 CN CN201480008231.5A patent/CN105228651A/zh active Pending
- 2014-01-02 AU AU2014204043A patent/AU2014204043A1/en not_active Abandoned
- 2014-01-02 PE PE2015001246A patent/PE20151980A1/es not_active Application Discontinuation
- 2014-01-03 US US14/147,167 patent/US20140193827A1/en not_active Abandoned
-
2015
- 2015-06-29 IL IL239692A patent/IL239692A0/en unknown
- 2015-07-03 CL CL2015001915A patent/CL2015001915A1/es unknown
- 2015-07-24 ZA ZA2015/05367A patent/ZA201505367B/en unknown
-
2017
- 2017-05-28 IL IL252547A patent/IL252547A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504039A5 (enExample) | ||
| Legoux et al. | MAIT cell development and functions: the microbial connection | |
| Peng et al. | CTLs heterogeneity and plasticity: implications for cancer immunotherapy | |
| US10822587B2 (en) | T cell balance gene expression, compositions of matters and methods of use thereof | |
| US11209440B2 (en) | T cell balance gene expression, compositions of matters and methods of use thereof | |
| JP2021072778A5 (enExample) | ||
| Yi et al. | Identifcation of differentially expressed long non-coding RNAs in CD4+ T cells response to latent tuberculosis infection | |
| JP2016504039A (ja) | グラチラマーアセテート関連医薬品の特性決定 | |
| GB2576680A (en) | Systems and methods for generating, visualizing and classifying molecular functional profiles | |
| Fattori et al. | CD25high effector regulatory T cells hamper responses to PD-1 blockade in triple-negative breast cancer | |
| CN111593022B (zh) | vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用 | |
| Thiébaut et al. | Gene expression signatures associated with immune and virological responses to therapeutic vaccination with dendritic cells in HIV-infected individuals | |
| IL312027A (en) | Methods for culturing immune cells | |
| Zhang et al. | Dynamic immune status analysis of peripheral blood mononuclear cells in patients with Klebsiella pneumoniae bloodstream infection sepsis using single-cell RNA sequencing | |
| Gutiérrez-Reyna et al. | IL-12 Signaling Contributes to the Reprogramming of Neonatal CD8+ T Cells | |
| Gong et al. | Unveiling the immunological landscape of disseminated tuberculosis: a single-cell transcriptome perspective | |
| Nygrén et al. | High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia | |
| CN116694568A (zh) | 用于激活整体抗肿瘤免疫系统的培养基配方物及制备激动剂激活的整体免疫效应细胞的方法 | |
| Iyoda et al. | Augmenting Granzyme B–Expressing NK Cells by Invariant NKT Ligand–Loaded APCs in Patients with Postoperative Early Stage Non–Small Cell Lung Cancer: Results of a Randomized Phase II Study | |
| Luo et al. | CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy | |
| Nussenblatt et al. | National Institutes of Health Center for Human Immunology Conference, September 2009: Meeting the human immunology challenge | |
| WO2026088096A1 (en) | Treatment of systemic sclerosis using a population of cd19 car-expressing cells | |
| Puri et al. | Identification of the potential molecular biomarkers of COVID-19 and the associated drugs: a bioinformatics approach | |
| Lei | Deciphering m eloid (progenitor) cell function and communication in (tumor) tissues | |
| Li et al. | Single-cell RNA-sequencing identifies a novel subset of CD9+ reparative macrophages modulated by CCN2 derived from Nlrx1 deficient cardiomyocytes in the infarcted heart |